Researchers from the CoEHAR at the University of Catania, together with international experts from the DiaSmokeFree Working Group, aimed to answer these questions: what could be the effects of smoking cessation on the efficacy and safety of antidiabetic drugs? Could significant changes occur that would require a readjustment of pharmacological treatments?
Diasmoke 2.0 is a CoEHAR research project that aims to assess health improvements and changes in cardiovascular risk factors in smokers with Type 2 Diabetes Mellitus who switch to combustion-free nicotine delivery systems
Helping diabetic patients who smoke to choose a healthier and less harmful alternative to reduce smoking-related health issues is our mission.
On Monday 22 March from 9.30 to 17.00 CET, on the Zoom platform, the CoEHAR (Center of Excellence for the acceleration of Harm Reduction) will hold the kick off meeting…
We will send you direct emails, without intermediary services, you can withdraw in time by replying directly to the newsletter
Copyright 2021 – Center of Excellence for the acceleration of Harm Reduction. All rights reserved.